Shield Therapeutics PLC Grant of Share Options (7531K)
July 11 2017 - 8:59AM
UK Regulatory
TIDMSTX
RNS Number : 7531K
Shield Therapeutics PLC
11 July 2017
Shield Therapeutics plc
("Shield" or the "Company")
Grant of Share Options
London, UK, 11 July 2017. Shield Therapeutics plc (LSE:STX), a
specialty pharmaceutical company focused on secondary care,
announces that the Company has today granted, in aggregate,
1,972,487 share awards in the form of options over Ordinary shares
in the capital of the Company ("Ordinary Shares") under the
Company's 2016 Long-term Incentive Plan ("LTIP") and the 2016
Company Share Option Plan ("CSOP"). The Company has granted
1,683,877 options under the LTIP and 288,610 options under the
CSOP.
The LTIP options will be exercisable at a price of 1.5 pence per
Ordinary Share, after a period of 3 years until the day before the
tenth anniversary of the grant, subject to the achievement of clear
performance criteria set out in the Company's Admission Document, a
copy of which is available on the Company's website
(www.shieldtherapeutics.com).
The CSOP options are exercisable at an exercise price of 157.5
pence per Ordinary Share from the third anniversary of grant until
the day before the tenth anniversary of grant. There are no
additional performance conditions attaching to the CSOP
options.
This grant of options is part of the Company's long-term
incentive arrangements designed to align the interests of the
shareholders and executives.
In accordance with the requirements of the EU Market Abuse
Regulation the following options have been granted to PDMRs under
the LTIP and CSOP.
Total number
of LTIP Total number
LTIP options of CSOP options
options held following CSOP options held following
Name granted grant granted grant
Carl Sterritt,
CEO 263,512 572,736 19,048 19,048
Joanne Estell,
CFO 285,714 285,714 19,048 19,048
Paul Steckler,
PDMR 162,698 356,618 19,048 19,048
Mark Sampson,
PDMR 165,952 321,088 19,048 19,048
Following the grant of the LTIP and CSOP options, the total
number of Ordinary Shares outstanding under share incentive schemes
arrangements will be 3,014,749 representing 2.59% of the Company's
issued share capital.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
LTIP
1 Details of the person discharging managerial
responsibilities/person closely associated
--- -------------------------------------------------------------------
a) Name Carl Sterritt Director / PDMR
Joanne Estell Director / PDMR
Paul Steckler PDMR
Mark Sampson PDMR
--- ------------------------- ----------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------
a) Position/status All PDMRs of Shield Therapeutics
--- ------------------------- ----------------------------------------
b) Initial Initial Notification
notification/
Amendment
--- ------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------------
a) Name Shield Therapeutics plc
--- ------------------------- ----------------------------------------
b) LEI 213800G74QWY15FC3W71
--- ------------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -------------------------------------------------------------------
a) Description Option over ordinary shares of 1.5p
of the each in the capital of the Company
financial ISIN of Ordinary Shares: GB00BYV81293
instrument,
type of
instrument
Identification
code
--- ------------------------- ----------------------------------------
b) Nature Grant of Options over ordinary shares
of the in accordance
transaction with the Company's Long Term Incentive
Plan
--- ------------------------- ----------------------------------------
c) Price(s) Exercise price: 1.5p
and volume(s) Volumes:
Carl Sterritt 263,512
Joanne Estell 285,714
Paul Steckler 162,698
Mark Sampson 165,952
--- ------------------------- ----------------------------------------
d) Aggregated
information 877,876
Exercise price: 1.5p
* Aggregated volume
* Price
--- ------------------------- ----------------------------------------
e) Date of 11 July 2017
the transaction
--- ------------------------- ----------------------------------------
f) Place Outside a trading venue
of the
transaction
--- ------------------------- ----------------------------------------
CSOP
1 Details of the person discharging managerial
responsibilities/person closely associated
--- -------------------------------------------------------------------
a) Name Carl Sterritt Director / PDMR
Joanne Estell Director / PDMR
Paul Steckler PDMR
Mark Sampson PDMR
--- ------------------------- ----------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------
a) Position/status All PDMRs of Shield Therapeutics
--- ------------------------- ----------------------------------------
b) Initial Initial Notification
notification/
Amendment
--- ------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------------
a) Name Shield Therapeutics plc
--- ------------------------- ----------------------------------------
b) LEI 213800G74QWY15FC3W71
--- ------------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -------------------------------------------------------------------
a) Description Option over ordinary shares of 157.5p
of the each in the capital of the Company
financial ISIN of Ordinary Shares: GB00BYV81293
instrument,
type of
instrument
Identification
code
--- ------------------------- ----------------------------------------
b) Nature Grant of Options over ordinary shares
of the in accordance
transaction with the Company's Share Option Scheme
--- ------------------------- ----------------------------------------
c) Price(s) Exercise price: 157.5p
and volume(s) Volumes:
Carl Sterritt 19,048
Joanne Estell 19,048
Paul Steckler 19,048
Mark Sampson 19,048
--- ------------------------- ----------------------------------------
d) Aggregated
information
* Aggregated volume
76,192
Exercise price: 157.5p
* Price
--- ------------------------- ----------------------------------------
e) Date of 11 July 2017
the transaction
--- ------------------------- ----------------------------------------
f) Place Outside a trading venue
of the
transaction
--- ------------------------- ----------------------------------------
-Ends-
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive
Officer
Joanne Estell, Chief Financial
Officer
Nominated Advisor and Joint
Broker
Liberum Capital Limited
Christopher Britton/Steve
Pearce +44 (0)20 3100 2222
Joint Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Financial PR Advisor +44 (0)20 3709 5700
Consilium Strategic Communications shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott/Matthew
Neal
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of iron deficiency anaemia
(IDA) in adult patients with inflammatory bowel disease (IBD) which
has exclusive IP rights until the mid-2030's. In addition, the
Group is developing PT20, a late-stage pharmaceutical for the
treatment of systemic phosphate accumulation (hyperphosphatemia).
Shield Therapeutics, headquartered in London, is listed on LSE's
AIM under the ticker STX. For more information please visit
www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUAVORBBABAAR
(END) Dow Jones Newswires
July 11, 2017 09:59 ET (13:59 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024